A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 39.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 31.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ...

FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Comp ...

Terns Pharmaceuticals, Inc. (TERN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39926 Terns Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1448275 (State or other jurisdic ...

Exhibit 99.1 TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML) • Dose escalation in Phase 1 CARDINAL study completed in January 2025 • Terns previously announced positive interim data from the Phase 1 CARDINAL trial of TERN-701, demonstrating: o Compelling molecular responses starting at the lowest dose in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels o Encouraging safety profile with no dose limiting toxicities, adverse eve ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-st ...

Core Viewpoint - Terns Pharmaceuticals is positioned as a small-cap biotech with significant upside potential in the weight loss therapeutic area, particularly with its investigational drugs TERN-601 and TERN-501, which are nearing phase 2 studies [1][2]. Group 1: Company Overview - Terns Pharmaceuticals focuses on developing weight loss and oncology medicines, with TERN-601 and TERN-501 as its leading candidates in the anti-obesity field [2][3]. - The average price target for Terns Pharmaceuticals' stock is $19.06, suggesting a potential increase of approximately 462% from current levels [2]. Group 2: Product Pipeline - TERN-601 is a potential once-daily oral GLP-1 medicine, which could appeal to patients preferring oral formulations over injected alternatives. In a phase 1 study, it achieved a statistically significant mean weight loss of 5.5% [2]. - TERN-501 aims to enhance the efficacy of GLP-1 medicines by stabilizing energy expenditures during weight loss, which could lead to its standard use alongside GLP-1 therapies if proven effective [3]. Group 3: Clinical Development - Terns Pharmaceuticals is also developing TERN-701, a potential cancer treatment that has shown positive interim data in a phase 1 study for chronic myeloid leukemia, with more data expected in the fourth quarter [4]. - Both TERN-601 and TERN-501 have not yet entered phase 2 studies, and their mid-stage data could serve as major catalysts for the stock price [5]. Group 4: Market Competition and Challenges - The competitive landscape for oral GLP-1 medicines is intensifying, with other companies advancing ahead of Terns Pharmaceuticals in this area [7][8]. - Terns previously abandoned the development of TERN-501 for metabolic dysfunction-associated steatohepatitis (MASH) after phase 2 trials, highlighting the challenges in developing successful therapies in crowded fields [6][7].

Core Points - Terns Pharmaceuticals, Inc. has granted an equity inducement award to Andrew Gengos, the new chief financial officer, as a material inducement for his acceptance of employment [1] - The equity award consists of an option to purchase 750,000 shares of Terns common stock at an exercise price of $3.73, which is the closing price on February 24, 2025 [2] - The option has a 10-year term and vests over four years, contingent on Mr. Gengos' continued service [2] Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases such as oncology and obesity [3] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [3]

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib Introduces TERN-601 Phase 2 FALCON obesity study design; on track to initiate study in early 2Q25 with 12-week data expected 2H25 Cash and cash equivalents expected to provide runway into 2028 FOSTER CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ...